Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2003

View Archived Issues

Novel series of HIV protease inhibitors described in recent patent

Two series of IgE antibody production inhibitors identified by Kowa scientists

Tularik presents novel modulators of UPC3 with utility in obesity and diabetes

Spanish team presents novel COX-2 inhibitors in recent patent

Label for Botox widened in Europe

Xenova reports progress in 2002

CV Therapeutics presents novel adenosine A2B antagonists

Ube scientists identify novel series of leukotriene receptor antagonists

Novel alpha2- and/or alpha3-selective GABA-A receptor modulators covered by Merck patent

New PAI-1 inhibitors in early development at Tanabe Seiyaku

Organix and Virginia Commonwealth U. describe novel CB1 modulators

Eisai establishes neuroscience drug discovery research program at Kyoto University

MorphoSys and Boehringer Ingelheim collaborate on therapeutic antibodies

Manhattan Pharmaceuticals and Atlantic Technology Ventures complete merger

Metvix PDT recommended for approval in Australia

Organon and Ligand to copromote Avinza in U.S.

EMEA accepts bortezomib MAA for review

Approval sought for once-daily Reminyl

Nuvelo reveals alfimeprase program progress in 2002

Dukoral approved in Canada

Abilify sNDA submitted for long-term treatment of schizophrenia

Candidacidal alpha-MSH peptide analogues discovered at Zengen

Orphan medicinal product designation for Corixa's Bexxar product

Dendreon to acquire Corvas

New series of GH secretagogues designed by European research team

Binding kinetics and cardioprotective effects of sabiporide characterized

Antiangiogenic activity of FYK-1388 demonstrated in vitro and in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
New assay for drug discovery against chemo-induced peripheral neuropathy
BioWorld Science
A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...